Literature DB >> 19855923

Alanine-aminotransferase levels predict impaired glucose tolerance in a worksite population.

Christoph Oberlinner1, Andreas Zober, Peter P Nawroth, Per M Humpert, Michael Morcos.   

Abstract

Insulin resistance and impaired glucose tolerance precede the development of type 2 diabetes. In 2006, the BASF Occupational Medicine and Health Protection Department offered a diabetes screening program for 33,000 employees. 1,594 employees had their diabetes risk tested: 285 employees were at medium to high risk for diabetes type 2, according to the Finrisk score. Hundred and fifty-seven of these individuals underwent oral glucose tolerance testing: 22 were shown to have impaired glucose tolerance (IGT), and 5 had manifest diabetes. Thus, 18% of this worksite sample population were affected by IGT or type 2 diabetes. A total of 87% were affected by metabolic syndrome (MS) according to the International Diabetes Federation (IDF) criteria. At baseline, individuals with normal glucose tolerance and impaired glucose tolerance differed significantly with respect to fasting glucose (97 +/- 8 vs. 103 +/- 10 mg/dl, P < 0.01), HbA1c (5.5 +/- 0.3 vs. 5.7 +/- 0.4%, P < 0.01), and alanine-aminotransferase (ALT) (28 +/- 15 vs. 36 +/- 18 U/I, P < 0.05). In binary logistic regression analysis adjusted for age and gender, fasting glucose and ALT were the only independent predictors of impaired glucose tolerance (OR 4.8 [1.24-24.8] and OR 5.5 [1.2-24.8]), while age and HbA1c had only borderline significance (OR 3.9 [0.94-15.92] and OR 2.8 [0.94-8.67]). Waist circumference, BMI, triglycerides, and HDL as central components of the MS had no predictive value for impaired glucose tolerance. In summary, in this particular sample population, fasting glucose and ALT were the only significant predictors of IGT. These data point to an important role of the liver in insulin resistance and the development of impaired glucose tolerance in the relatively young and small population studied.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19855923     DOI: 10.1007/s00592-009-0148-x

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  3 in total

1.  Dextran sulfate sodium inhibits alanine synthesis in Caco-2 cells.

Authors:  Zhong Ye; Darya O Mishchuk; Natasha S Stephens; Carolyn M Slupsky
Journal:  Int J Mol Sci       Date:  2011-04-04       Impact factor: 5.923

2.  Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.

Authors:  Alison J Dawson; Eric S Kilpatrick; Anne-Marie Coady; Abeer M M Elshewehy; Youssra Dakroury; Lina Ahmed; Stephen L Atkin; Thozhukat Sathyapalan
Journal:  BMC Endocr Disord       Date:  2017-07-14       Impact factor: 2.763

3.  Considering serum alanine aminotransferase and gamma-glutamyltransferase levels together strengthen the prediction of impaired fasting glucose risk: a cross-sectional and longitudinal study.

Authors:  Ji Hye Jeong; Susie Jung; Kyu-Nam Kim
Journal:  Sci Rep       Date:  2021-02-09       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.